71 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Progress in discovery of small-molecule modulators of protein-protein interactions via fragment screening.
Pfizer
Bisphenol A binds to Ras proteins and competes with guanine nucleotide exchange: implications for GTPase-selective antagonists.
Ruhr University of Bochum
Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.
The University of Arizona
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
Universite£
Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-
Shanghai Jiao Tong University
Identification of novel Pyrrolo[2,3-d]Pyrimidine-based KRAS G12C inhibitors with anticancer effects.
Sun Yat-Sen University
Structure-Based Design and Synthesis of Potent and Selective KRAS G12D Inhibitors.
Erasca
Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRAS
Astrazeneca
A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives.
China Pharmaceutical University
JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS
Novartis Institutes For Biomedical Research
Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS
Boehringer Ingelheim Rcv
Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRAS
Astrazeneca
Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening.
Southern Medical University
Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
Massachusetts College of Pharmacy and Health Sciences University
Drugging the Next Undruggable KRAS Allele-Gly12Asp.
University of California San Francisco
Accelerated Identification of Cell Active KRAS Inhibitory Macrocyclic Peptides using Mixture Libraries and Automated Ligand Identification System (ALIS) Technology.
Merck
KRAS Inhibitors and Target Engagement Technology: From Undruggable to Druggable Targets in Cancer Therapeutics.
Usona Institute
Cyclic Peptide Screening Methods for Preclinical Drug Discovery.
University of Washington
Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents.
Sun Yat-Sen University
Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity.
Astellas Pharma
Targeting a Novel KRAS Binding Site: Application of One-Component Stapling of Small (5-6-mer) Peptides.
Cambridge University
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
Mirati Therapeutics
A Series of Pyrazole Analogs Binding to KRASG12C as Potential Cancer Treatment.
Arrival Discovery
Targeting KRAS G12D Mutant for the Potential Treatment of Pancreatic Cancer.
Usona Institute
Targeting KRAS Mutant Protein Inhibitor for Potential Treatment in Cancer.
Usona Institute
Dual Inhibition of KRAS G12C and G12D Mutants as a Potential Treatment in Cancer Therapy.
Usona Institute
Small Molecule Inhibitors of KRAS Mutant as a Therapeutic Strategy for the Treatment of Cancer.
Usona Institute
Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS
Shanghai Institute of Materia Medica (Simm)
De-risking Drug Discovery of Intracellular Targeting Peptides: Screening Strategies to Eliminate False-Positive Hits.
Msd
Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor.
Lilly Research Laboratories
Fragment-to-Lead Medicinal Chemistry Publications in 2019.
Novartis Institutes For Biomedical Research
Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
Jinan University
Chalcones bearing a 3,4,5-trimethoxyphenyl motif are capable of selectively inhibiting oncogenic K-Ras signaling.
Wright State University
Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS
Astrazeneca
Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
China Pharmaceutical University
Inhibitors of KRAS May Potentially Provide Effective Cancer Treatment.
Therachem Research Medilab
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.
Array Biopharma
Discovery of covalent enzyme inhibitors using virtual docking of covalent fragments.
University of Houston
Precedence and Promise of Covalent Inhibitors of EGFR and KRAS for Patients with Non-Small-Cell Lung Cancer.
Pfizer
Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d.
Takeda Pharmaceutical
Investigation of the structural requirements of K-Ras(G12D) selective inhibitory peptide KRpep-2d using alanine scans and cysteine bridging.
Takeda Pharmaceutical
RET inhibitors, pharmaceutical compositions and uses thereof
Sunshine Lake Pharma Co.
ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO
Arena Pharmaceuticals
COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF
Medifron Dbt
Potent and selective inhibitors of monoamine transporters; method of making; and use thereof
The Usa, As Represented By The Secretary, Dhhs